PrimeGen Leverages SPAC's Fundraising Capacity in $1.5B Going-Public Push

PrimeGen US, a biotechnology innovator in regenerative medicine, announced plans to enter the public markets through a strategic merger with blank-check company DT Cloud Star Acquisition, capitalizing on SPAC’s capital-raising capabilities. The transaction, valued at $1.5 billion, is expected to close in the second half of 2026, with the combined entity set to trade on the Nasdaq Stock Exchange under the PrimeGen US name.

Tapping SPAC’s Capital Capacity in a Competitive Biotech Landscape

The shift toward SPAC mergers reflects a broader industry trend among biotech companies seeking alternative pathways to public markets. Unlike traditional IPOs, which require extensive regulatory submissions and investor roadshows, SPAC structures offer companies immediate access to capital while bypassing certain procedural delays. This fundraising capacity has become particularly attractive to emerging biotech firms pursuing complex and capital-intensive research programs. DT Cloud Star Acquisition serves as an investment vehicle specifically designed to identify and merge with high-potential companies in transformative sectors.

PrimeGen’s Stem Cell Therapy Pipeline and Clinical Vision

The company specializes in developing cutting-edge stem cell therapies, with primary applications targeting acute liver injury and associated critical organ dysfunction. This therapeutic focus addresses a significant clinical gap, as current treatment options for acute hepatic failure remain limited. PrimeGen’s research pipeline represents the kind of high-impact innovation that institutional investors increasingly prioritize when evaluating pre-public biotech opportunities. The company’s merger with DT Cloud Star Acquisition provides the financial runway needed to advance clinical trials and accelerate regulatory approval pathways.

Public Market Debut and Strategic Implications

By completing this SPAC transaction in the latter half of 2026, PrimeGen US will gain direct capital market access and enhanced operational flexibility as a publicly traded entity. This timing allows the company to position itself amid growing investor enthusiasm for regenerative medicine solutions. The transaction underscores how SPAC capacity continues to reshape biotech financing dynamics, enabling promising companies to achieve public status while maintaining focus on their core research and development objectives.